OCEA (Ocean Biomedical) EBIT: $-28.97 Mil (TTM As of Mar. 2025)

What is Ocean Biomedical EBIT?

Ocean Biomedical OCEA -50.00% EBIT is $-28.97 Mil as of Mar. 2025.

Ocean Biomedical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2025 was $-7.90 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was $-28.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ocean Biomedical's annualized ROC % for the quarter that ended in Mar. 2025 was -28.26%. Ocean Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ocean Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -309.05%.

Ocean Biomedical (OTCPK:OCEA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ocean Biomedical's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

	ROC % (Q: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Mar. 2025 ))	/ count )
=	-3.832 * ( 1 - 0% )	/	( (17.479	+	9.638)	/ 2 )
=	-3.832	/	13.5585
=	-28.26 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.902	-	16.5	-	( 0	-	max(0, 33.889	-	0.812	+	0	))
=	17.479

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.582	-	17.02	-	( 0	-	max(0, 26.568	-	1.492	+	0	))
=	9.638

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Ocean Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Mar. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-31.588	/	( ( (0 + max(-16.777, 0))	+	(0 + max(-15.726, 0)) )	/	2 )
=	-31.588	/	( ( 0	+	0 )	/	2 )
=	-31.588	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.812)	-	(16.5	+	0	+	1.089)
=	-16.777

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.492)	-	(17.02	+	0	+	0.198)
=	-15.726

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ocean Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2025 )
	=	-28.967	/	9.373
	=	-309.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical EBIT Related Terms

Ocean Biomedical EBIT Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's EBIT can be seen below:

Ocean Biomedical EBIT Chart

Ocean Biomedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-1.65

-62.35

-16.12

-112.70

-7.43

Ocean Biomedical Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT	Get a 7-Day Free Trial															13.64	-16.72	-5.07	0.72	-7.90

OCEA vs SIGY, ENDV, SCPX: EBIT Comparison

For the Biotechnology subindustry, Ocean Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocean Biomedical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's EV-to-EBIT falls into.

Save Embed

Ocean Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.97 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-28.97 Mil mean?

Ocean Biomedical (OCEA) has a EBIT of $-28.97 Mil as of Mar. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ocean Biomedical.

Is Ocean Biomedical's EBIT too high?

Ocean Biomedical's current EBIT is $-28.97 Mil.

How does Ocean Biomedical's EBIT compare to SIGY and ENDV?

Ocean Biomedical's EBIT of $-28.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ocean Biomedical. Ocean Biomedical's current EBIT is $-28.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ocean Biomedical stock overvalued right now?

Ocean Biomedical (OCEA) has a current EBIT of $-28.97 Mil. The current EBIT is $-28.97 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current EBIT is $-28.97 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Industry Healthcare Biotechnology

Comparable Companies SIGY ENDV SCPX RGBP CNBX WINT VINC HEPA ATXI RMTG VRTX REGN XBRU:UCB XKRX:207940 XBRU:ARGX ASX:CSL ALNY ONC XKRX:068270 INSM

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903

Website https://www.oceanbiomedical.com

Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.